News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55

Al's Comment:

 Impressive results. 20% complete response rate form a single injection of this drug, and no serious side effects.  This is the type of treatment that should be approved immediately.


Posted on: 11/15/2017

Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740